Bildkälla: Stockfoto

Saniona: Milestone for the Ion Channel Platform - Redeye

Redeye recognizes a milestone and signal value that SAN711 has entered a phase 1 clinical study.

Redeye recognizes a milestone and signal value that SAN711 has entered a phase 1 clinical study.
Börsvärldens nyhetsbrev
ANNONSER